Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients

European Journal of Cancer

Volumn 64, Issue , 2016, Pages 167-174

  Caballero Baños, Miguel ^a   Benitez Ribas, Daniel ^b   Tabera, Jaime ^c   Varea, Sara ^a   Vilana, Ramon ^b   Bianchi, Luis ^b   Ayuso, Juan Ramón ^b   Pagés, Mario ^b   Carrera, Gemma ^d   Cuatrecasas, Miriam ^a   Martin Richard, Marta ^e   Cid, Joan ^a   Lozano, Miguel ^a   Castells, Antoni ^b   García Albéniz, Xabier ^f   Maurel, Joan ^a   Vilella, Ramon ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c BST   (Spain)

^d Hospital Platón   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cancer; Colorectal; Dendritic cells; Immunotherapy; Vaccine

Indexed keywords

AUTOLOGOUS TUMOUR LYSATE DENDRITIC CELL VACCINE; CANCER VACCINE; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ADVERSE DRUG REACTION; AGED; ANEMIA; ARTICLE; ASTHENIA; BEST SUPPORTIVE CARE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER PATIENT; CHILL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; LEUKOPENIA; MALE; METASTATIC COLORECTAL CANCER; MYALGIA; NAUSEA; ORAL MUCOSITIS; OVERALL SURVIVAL; PATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; T LYMPHOCYTE; THROMBOCYTOPENIA; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DENDRITIC CELL; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; SECONDARY; SURVIVAL ANALYSIS; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SURVIVAL ANALYSIS;

EID: 84978532202     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.06.008     Document Type: Article

References (14)

1. Grothey, A., Cutsem, E.V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 303–312.
2. Khan, K., Cunningham, D., Chau, I., Targeting angiogenic pathways in colorectal cancer: complexities, challenges and future directions. Curr Drug Targets 16 (Mar 25, 2015), 1–16.
3. Palucka, K., Banchereau, J., Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12 (2012), 265–277.
4. Widen, K., Mozaffari, F., Choudhury, A., Mellstedt, H., Overcoming immunosuppressive mechanisms. Ann Oncol 19:Suppl. 7 (2008), 241–247.
5. Anguille, S., Smits, E.L., Lion, E., van Tendeloo, V.F., Berneman, Z.N., Clinical use of dendritic cells for cancer therapy. Lancet Oncol 15 (2014), 257–267.
6. Kavanagh, B., Ko, A., Venook, A., Margolin, K., Margolin, K., Zeh, H., Lotze, M., et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 30 (2007), 762–772.
7. Toh, H.C., Wang, W.W., Chia, W.K., Kvistborg, P., Sun, L., Teo, K., et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin Cancer Res 15 (2009), 7726–7736.
8. Barth, R.J. Jr., Fisher, D.A., Wallace, P.K., Channon, J.Y., Noelle, R.J., Gui, J., et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res 16 (2010), 5548–5555.
9. Venderbosch, S., Nagtegaal, I.D., Maughan, T.S., Smith, C.G., Cheadle, J.P., Fisher, D., et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 20 (2014), 5322–5330.
10. Llosa, N.J., Cruise, M., Tam, A., Wicks, E.C., Hechenbleikner, E.M., Taube, J.M., et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5 (2015), 43–51.
11. Feig, C., Jones, J.O., Kraman, M., Wells, R.J., Deonarine, A., Chan, D.S., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 10:110 (2013), 20212–20217.
12. Mace, T.A., Ameen, Z., Collins, A., Wojcik, S., Mair, M., Young, G.S., et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 73 (2013), 3007–3018.
13. Wolchok, J.D., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbé, C., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
14. Hoos, A., Evolution of end points for cancer immunotherapy trials. Ann Oncol 23:Suppl. 8 (2012), viii47–viii52.